New pharmacokinetic and cardiac biomarker data further demonstrate ifetroban's potential to protect the heart and reduce cardiac damage in DMD patientsNASHVILLE, Tenn., June 23, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company committed to developing new products for rare diseases, shared the latest positive results from its Phase 2 FIGHT DMD trial evaluating ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease, at the ann ...

Edgewise Therapeutics (EWTX) 2025 Conference May 20, 2025 09:00 AM ET Speaker0 Thanks everyone for being here. Our next presenting company is Edgewise Therapeutics represented by Kevin, their c CEO, and Broad, their chief operating officer. So thanks for being here. Speaker1 Thank you, Kymena. Great. Yeah. Speaker0 So maybe we'll just jump right in. I mean, recently, you guys reported four week data for EDG seven thousand five hundred in HCM, and it's got a fairly unique efficacy profile. So maybe can you c ...